The New Payer Dogma: US FDA Approved Drugs Have 'Less Evidence'

It is now a common assertion among insurers that one of the many challenges they face in covering high-priced specialty therapies is that drugs are approved with “less evidence” than used to be the case. That is more myth than reality – but a very dangerous myth if it isn’t corrected by the US FDA and the drug industry.

Forensic_Evidence

It is now accepted as an established truth among payers that new drugs approved by US Food & Drug Administration in recent years have less efficacy evidence than used to be expected.

During one recent industry conference hosted by a leading specialty pharmacy company, that assertion was made repeatedly as one of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approval Standards

More from Pathways & Standards